Holen Sie sich die Stockscreener-App
15.50
1.24%
0.19
Handel nachbörslich:
15.50
Schlusskurs vom Vortag:
$15.31
Offen:
$15.55
24-Stunden-Volumen:
54,111
Relative Volume:
1.09
Marktkapitalisierung:
$2.70B
Einnahmen:
$603.63M
Nettoeinkommen (Verlust:
$468.71M
KGV:
5.7793
EPS:
2.682
Netto-Cashflow:
$-59.92M
1W Leistung:
+5.66%
1M Leistung:
-3.67%
6M Leistung:
+3.33%
1J Leistung:
-15.67%
1-Tages-Spanne:
$15.45
$15.77
1-Wochen-Bereich:
$14.40
$15.77
52-Wochen-Spanne:
$11.51
$19.50
Hutchmed China Limited Adr Stock (HCM) Company Profile
Vergleichen Sie HCM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HCM
Hutchmed China Limited Adr
|
15.50 | 2.63B | 603.63M | 468.71M | -59.92M | 2.682 |
|
ZTS
Zoetis Inc
|
124.46 | 63.97B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.56 | 42.40B | 29.63B | 260.53M | 4.77B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.32 | 41.77B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.46 | 23.54B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
437.33 | 18.89B | 3.08B | 1.24B | 1.07B | 25.61 |
Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-22 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2025-05-13 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-11-24 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-05-04 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-09-22 | Herabstufung | Goldman | Buy → Neutral |
| 2021-08-03 | Eingeleitet | Jefferies | Buy |
| 2020-10-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-03-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-02-20 | Eingeleitet | Goldman | Buy |
| 2019-11-19 | Eingeleitet | CLSA | Buy |
| 2019-10-23 | Bestätigt | BofA/Merrill | Buy |
| 2019-07-05 | Eingeleitet | Macquarie | Outperform |
Alle ansehen
Hutchmed China Limited Adr Aktie (HCM) Neueste Nachrichten
Hutchmed Strengthens Position Within FTSE AIM 100 Index Healthcare Sphere - Kalkine Media
Hutchmed takes wraps off expanding oncology pipeline - Sharecast.com
Market news - investments.halifax.co.uk
HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event - The Manila Times
CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025 - The Manila Times
International companies to host live webcasts at Deutsche - GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025 - Yahoo Finance
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Vanguard Personalized Indexing Management LLC Grows Holdings in Sandstorm Gold Ltd $SAND - Defense World
Hutchmed upbeat on preclinical data for novel cancer therapy - Sharecast.com
RCSHutchmed China LtdHUTCHMED Presents Data at AACR NCI EORTC - TradingView
HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - The Manila Times
HUTCHMED Highlights HMPL-A251 Data Presented at the - GlobeNewswire
Allianz Asset Management GmbH Sells 80,000 Shares of HUTCHMED (China) Limited Sponsored ADR $HCM - MarketBeat
Will Can Fite Biopharma Ltd Sponsored ADR stock benefit from mergersQuarterly Risk Review & Risk Controlled Stock Alerts - Trung tâm Dự báo KTTV quốc gia
Pfizer: CN Biopharma Sector Shows Astonishing Growth; US Drug Industry Must Collaborate with CN - AASTOCKS.com
HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress - GlobeNewswire
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Why HUTCHMED (China) Limited (Common Stock) (H7T1) stock is favored by hedge fundsTrade Exit Report & Technical Entry and Exit Alerts - newser.com
Will HUTCHMED (China) Limited (Common Stock) (H7T1) stock deliver stable dividendsPortfolio Update Report & Verified Chart Pattern Signals - newser.com
BOCOMI: Trump's Additional Tariffs on Imported Innovative Drugs May Have Limited Actual Impact on CN Pharmas - AASTOCKS.com
HUTCHMED (NASDAQ:HCM) Shares Gap DownTime to Sell? - MarketBeat
M Stanley: Increased Recognition Pushes Biotech Stocks to Outpace Mkt - AASTOCKS.com
Best Momentum Stock to Buy for August 19th - MSN
National Research Corporation $NRC Shares Sold by Goldman Sachs Group Inc. - Defense World
HUTCHMED (China) Limited Sponsored ADR $HCM Stock Position Raised by Goldman Sachs Group Inc. - Defense World
HUTCHMED (NASDAQ:HCM) Shares Gap UpHere's What Happened - MarketBeat
HUTCHMED (NASDAQ:HCM) Shares Gap Up – Should You Buy? - Defense World
Price action breakdown for HUTCHMED (China) Limited Depositary Receipt2025 Dividend Review & Risk Managed Investment Strategies - newser.com
Top Blockchain Stocks To Follow Now – September 12th - Defense World
HSBC Research Positive on LT Growth of CN Biotech, Favors INNOVENT BIO/ HANSOH PHARMA - AASTOCKS.com
G Sachs Gives ST Risk Analysis for 3 Types of Firms as US Reportedly Planning to Tighten Scrutiny on CN Innovative Drugs Could Pose 'Headline Risks' for CN Pharmas - AASTOCKS.com
CN SASAC Advocates to Accelerate Development of Central SOEs in the Biopharmaceutical Industry, Build National Team in Such Field - AASTOCKS.com
Intraday pattern recognizer results for HUTCHMED (China) Limited Depositary Receipt2025 Biggest Moves & Trade Opportunity Analysis Reports - Newser
Combining machine learning predictions for HUTCHMED (China) Limited Depositary ReceiptQuarterly Market Review & Verified Entry Point Signals - Newser
How moving averages guide HUTCHMED (China) Limited Depositary Receipt trading2025 Retail Activity & Stepwise Trade Signal Implementation - Newser
HUTCHMED Announces Appointment of Acting Chief Executive Officer - GlobeNewswire Inc.
Solventum Corporation $SOLV Shares Sold by Russell Investments Group Ltd. - Defense World
HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China - GlobeNewswire
Best Momentum Stock To Buy For August 19th - Barchart.com
How to build a custom watchlist for HUTCHMED (China) Limited Depositary Receipt2025 Price Action Summary & Verified Momentum Stock Ideas - Newser
BOCOMI Lowers HUTCHMED's TP to HKD37.6; Rating Kept Buy - AASTOCKS.com
Will HUTCHMED (China) Limited Depositary Receipt bounce back from current supportFree Oversold Recovery Opportunity Stocks - Newser
Analysts Have Conflicting Sentiments on These Healthcare Companies: Zymeworks (ZYME), HUTCHMED (HCM) and Zai Lab (ZLAB) - The Globe and Mail
Trend analysis for HUTCHMED (China) Limited Depositary Receipt this weekStock Holding Strategy Long-Term Summary Sheet - Newser
Carvana Co. (NYSE:CVNA) Major Shareholder Sells $35,236,000.00 in Stock - Defense World
Crossmark Global Holdings Inc. Sells 414 Shares of Morningstar, Inc. (NASDAQ:MORN) - Defense World
6,121 Shares in John Hancock Multifactor Large Cap ETF (NYSEARCA:JHML) Bought by Crossmark Global Holdings Inc. - Defense World
Concurrent Investment Advisors LLC Acquires New Holdings in ADMA Biologics Inc (NASDAQ:ADMA) - Defense World
Crossmark Global Holdings Inc. Has $356,000 Holdings in Nordson Corporation (NASDAQ:NDSN) - Defense World
Buenaventura Mining (NYSE:BVN) vs. Hochschild Mining (OTCMKTS:HCHDF) Head-To-Head Review - Defense World
Finanzdaten der Hutchmed China Limited Adr-Aktie (HCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.60%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):